Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated November 27, 2023, reports positive interim efficacy results from the DREAMM-7 Phase III clinical trial. The trial evaluates Blenrep (belantamab mafodotin) as a second-line treatment for relapsed or refractory multiple myeloma.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical trial update and does not contain financial statement data.
Material Changes and Clinical Results
- Primary Endpoint Met: The trial met its primary endpoint of progression-free survival (PFS). Blenrep plus BorDex (bortezomib plus dexamethasone) showed a statistically significant PFS benefit versus daratumumab plus BorDex.
- Overall Survival Trend: A strong and clinically meaningful overall survival (OS) trend was observed with a nominal p value < 0.0005. The trial continues to follow up for OS.
- Early Unblinding: The trial was unblinded early based on a recommendation from the Independent Data Monitoring Committee (IDMC).
- Safety Profile: The safety and tolerability of the Blenrep regimen were consistent with the known safety profiles of the individual agents.
- Study Design: 494 participants were randomized 1:1. Patients had previously received at least one prior line of therapy with documented disease progression.
Guidance, Outlook, and Management Commentary
Hesham Abdullah, Senior Vice President of Global Head Oncology R&D, stated that the results address a high unmet need in relapsed/refractory multiple myeloma, particularly given the head-to-head comparison with the daratumumab-based standard of care.
- Next Steps: Interim analysis results will be presented at an upcoming scientific meeting and shared with health authorities.
- Pipeline Outlook: The DREAMM-8 Phase III trial, evaluating Blenrep in combination with pomalidomide and dexamethasone versus bortezomib in combination with pomalidomide and dexamethasone, is ongoing. Data from DREAMM-8 are expected in the second half of 2024.
- Risks: Forward-looking statements are subject to risks and uncertainties, including those described in the company's 2022 Form 20-F and Q3 2023 results.
Key Facts for Investor Verification
- Confirm the statistical significance and hazard ratio details for the PFS benefit once full data is presented at the upcoming scientific meeting.
- Monitor the final Overall Survival (OS) data, as the current filing only reports a nominal p-value trend.
- Verify the regulatory submission timeline with health authorities following the interim analysis.
- Track the progress and expected data readout for the DREAMM-8 trial in H2 2024.
- Review the full safety data and adverse event profiles compared to the daratumumab control arm.